EFPIA - NEWSLETTER

EFPIA Newsletter 13 March 2025

News

11 March 2025 EFPIA response to the Critical Medicines Act

EFPIA supports the European Commission’s ambition to strengthen Europe’s medicines supply chain through the Critical...

10 March 2025 EFPIA begins legal proceedings in European court, to seek clarity on Urban Wastewater Treatment...

EFPIA believes that the obligations that the Directive imposes on producers of medicines run counter to key principles...

EU-X-CT: The Recommendations Public Consultation period is extended until 31st March

The public consultation for the EU-X-CT draft recommendations has been extended, giving you more time to share your feedback.

If you haven’t had the chance to review the recommendations, now is the time. Your insights are essential to ensuring these guidelines support safe and equitable access to cross-border clinical trials in Europe.

Review the draft and submit your comments here.

Learn more here.

Videos

Watch the webinar recording of "The case for investing in a healthier future for the EU"

In a time of slow economic growth, geopolitical instability, and increasing pressures on healthcare systems, strategic investment in health has never been more critical. Our upcoming report highlights the health and economic benefits of investing in prevention, early detection, and treatment of non-communicable diseases (NCDs) such as stroke, ischemic heart disease, type 2 diabetes, COPD, and breast cancer across the EU.

Discover MEP Stine Bosse's priorities for a healthier, more competitive Europe

In this short interview, MEP Stine Bosse discusses how we can make Europe healthier in the next EU mandate by ensuring access to healthcare and medicines for all European citizens. To achieve this, we need to strengthen Europe’s life sciences industry in today’s competitive global landscape.

Events

03 APR 2025

Unlocking efficiency through reliance: Navigating the EMA post-authorization framework... Virtual event

Learn more →

13 MAY 2025

International conference on protein stability – The gap between industry and administration... Södertälje Science Park, Sweden

The objective of this symposium/conference is to create an arena for discussions on the recent research and industrial...

Learn more →

Inspection landscape: Good Manufacturing and Distribution Practices (GMP/GDP)

Have a look at the new EFPIA leaflet "Inspection Landscape: Good Manufacturing and Distribution Practices". It outlines the main challenges and recommends approaches to streamline and enhance inspections, such as reliance pathways.

What we are reading

Preparing for the next pandemic with the CARE project 11 March 2025 (IHI)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶